Weekly versus Three-Weekly Cisplatin-based Concurrent Chemoradiotherapy as definitive treatment in Head and Neck Cancer- Where do we stand?

@article{Rawat2016WeeklyVT,
  title={Weekly versus Three-Weekly Cisplatin-based Concurrent Chemoradiotherapy as definitive treatment in Head and Neck Cancer- Where do we stand?},
  author={S. H. Rawat and Himanshu Srivastava and Parveen kumar Ahlawat and Ms.Mahua Pal and Gurudutt Gupta and Deepika Chauhan and Sarthak Tandon and Ruparna Khurana},
  journal={The Gulf journal of oncology},
  year={2016},
  volume={1 21},
  pages={
          6-11
        }
}
PURPOSE To compare toxicity, compliance, and early response of weekly and 3-weekly cisplatin administration concurrent with radiotherapy as definitive treatment in locally advanced squamous cell carcinoma head and neck. MATERIALS AND METHODS Patients with histologically proven stage III - IV B head and neck carcinoma presenting from June 2013 to March 2014 were randomly assigned to weekly (35 mg/m2, 6 cycles; arm A) and 3 weekly (100 mg/m2, 3 cycles; arm B) cisplatin with concurrent… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Treatment outcome of concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck

AE Azony, AM Sarhan, WE Hamouda
  • Z.U.M.J
  • 2012
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients

JP Pignon, A Le Maitre, E Maillard, J. Bourhis
  • Radiother Oncol
  • 2009
VIEW 1 EXCERPT